Jonathan D Alpern
Overview
Explore the profile of Jonathan D Alpern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith M, Ehresmann K, Knowlton G, LaFrance A, Benitez G, Quadri N, et al.
Am J Prev Med
. 2023 Jul;
65(6):993-1002.
PMID: 37406745
Introduction: Understanding of COVID-19-related disparities in the U.S. is largely informed by traditional race/ethnicity categories that mask important social group differences. This analysis utilizes granular information on patients' country of...
2.
Joo H, Maskery B, Alpern J, Weinberg M, Stauffer W
J Travel Med
. 2023 Apr;
31(6).
PMID: 37074145
Background: The risk of developing strongyloidiasis hyperinfection syndrome appears to be elevated among individuals who initiate corticosteroid treatment. Presumptive treatment or treatment after screening for populations from Strongyloides stercoralis-endemic areas...
3.
Ahiskali A, Drekonja D, Alpern J
JAMA Netw Open
. 2023 Apr;
6(4):e238592.
PMID: 37067802
No abstract available.
4.
Quadri N, Knowlton G, Benitez G, Ehresmann K, LaFrance A, DeFor T, et al.
JAMA Netw Open
. 2023 Apr;
6(4):e237877.
PMID: 37043199
Importance: Beyond traditional race and ethnicity demographic characteristics, additional discrete data variables are needed for informed health interventions in the US. Objective: To examine whether COVID-19 vaccine uptake patterns and...
5.
Alpern J, Joo H, Bahr N, Leventhal T
Open Forum Infect Dis
. 2023 Apr;
10(3):ofad118.
PMID: 37008563
Background: Nonadherence to antiviral therapy can lead to poor clinical outcomes among patients with chronic hepatitis B (CHB). We used a claims database to evaluate risk factors for nonadherence to...
6.
Park J, Joo H, Maskery B, Alpern J, Weinberg M, Stauffer W
J Travel Med
. 2023 Jan;
30(3).
PMID: 36718673
We estimated inpatient and outpatient payments for malaria treatment in the USA. The mean cost per hospitalized patient was significantly higher than for non-hospitalized patients (e.g. $27 642 vs $1177...
7.
Thomas C, Peterson J, Ahiskali A, Hamid L, Butts J, Czachura J, et al.
J Am Pharm Assoc (2003)
. 2022 Sep;
62(6):1848-1854.
PMID: 36068143
Background: The delivery of prompt and appropriate antimicrobial therapy for life-threatening infections is an important antimicrobial stewardship measure and a priority for hospitals. Objectives: To better understand U.S. hospital pharmacy...
8.
Thomas C, Stauffer W, Alpern J
Clin Infect Dis
. 2022 Sep;
76(3):e864-e866.
PMID: 36056897
Intravenous artesunate has been the global standard of care for severe malaria for over 2 decades. Yet, until recently, artesunate has only been available to patients through an expanded-access protocol...
9.
Pullen M, Alpern J, Bahr N
J Fungi (Basel)
. 2022 Aug;
8(8).
PMID: 36012812
Blastomycosis, caused by spp., is an endemic mycosis capable of causing significant disease throughout the body. Higher rates of infection are seen in the Mississippi and Ohio River valleys, the...
10.
Joo H, Maskery B, Alpern J, Chancey R, Weinberg M, Stauffer W
Am J Trop Med Hyg
. 2022 Aug;
107(4):841-844.
PMID: 35995136
Drug utilization and payment estimates for standard-of-care treatment of schistosomiasis have not been reported previously in the United States. This study estimates the utilization of praziquantel (standard-of-care drug) among patients...